A physiologically-based pharmacokinetic (PBPK) model of squalene-containing adjuvant in human vaccines Million A. TegengeRobert J. Mitkus Original Paper 04 August 2013 Pages: 545 - 556
On translation of antibody drug conjugates efficacy from mouse experimental tumors to the clinic: a PK/PD approach Nahor Haddish-BerhaneDhaval K. ShahAlison M. Betts Original Paper 10 August 2013 Pages: 557 - 571
Simultaneous optimal experimental design for in vitro binding parameter estimation C. Steven Ernest IIMats O. KarlssonAndrew C. Hooker Original Paper 13 August 2013 Pages: 573 - 585
Optimizing disease progression study designs for drug effect discrimination Sebastian UeckertStefanie HennigAndrew C. Hooker Original Paper 27 August 2013 Pages: 587 - 596
Second-generation minimal physiologically-based pharmacokinetic model for monoclonal antibodies Yanguang CaoJoseph P. BalthasarWilliam J. Jusko Original Paper 31 August 2013 Pages: 597 - 607
A mechanistic pharmacodynamic model of IRAK-4 drug inhibition in the Toll-like receptor pathway Ryan P. NolanAndrea G. BreeAnup Zutshi Original Paper 26 September 2013 Pages: 609 - 622